MA45129A - Traitements du cancer - Google Patents
Traitements du cancerInfo
- Publication number
- MA45129A MA45129A MA045129A MA45129A MA45129A MA 45129 A MA45129 A MA 45129A MA 045129 A MA045129 A MA 045129A MA 45129 A MA45129 A MA 45129A MA 45129 A MA45129 A MA 45129A
- Authority
- MA
- Morocco
- Prior art keywords
- cancer treatments
- treatments
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1609600.0A GB201609600D0 (en) | 2016-06-01 | 2016-06-01 | Cancer treatments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA45129A true MA45129A (fr) | 2021-05-05 |
Family
ID=56410849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA045129A MA45129A (fr) | 2016-06-01 | 2017-05-31 | Traitements du cancer |
Country Status (19)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2569185T3 (es) | 2011-03-01 | 2016-05-09 | Nucana Biomed Limited | Derivados de fosforamidato de 5-fluoro-2'-desoxiuridina para uso en el tratamiento del cáncer |
| PL3224268T3 (pl) | 2014-11-28 | 2019-11-29 | NuCana plc | Nowe pochodne 3'-deoksyadenozyny amidofosforanów estrów aminokwasów 2' i/lub 5' jako związki przeciwnowotworowe |
| GB201522764D0 (en) | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Formulations of phosphate derivatives |
| GB201609600D0 (en) | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
| GB201609601D0 (en) * | 2016-06-01 | 2016-07-13 | Nucana Biomed Ltd | Phosphoramidate compounds |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| GB201715011D0 (en) | 2017-09-18 | 2017-11-01 | Nucana Biomed Ltd | Floxuridine synthesis |
| CA3115712A1 (en) * | 2018-10-17 | 2020-04-23 | Xibin Liao | 6-mercaptopurine nucleoside analogues |
| JP2020164521A (ja) * | 2019-03-29 | 2020-10-08 | 国立大学法人 長崎大学 | 抗ウィルス薬 |
| KR20250133471A (ko) | 2020-02-18 | 2025-09-05 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 화합물 |
| TWI775313B (zh) | 2020-02-18 | 2022-08-21 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| CA3216162A1 (en) | 2021-04-16 | 2022-10-20 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
| WO2023023527A1 (en) | 2021-08-18 | 2023-02-23 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0317009D0 (en) * | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| GB0505781D0 (en) * | 2005-03-21 | 2005-04-27 | Univ Cardiff | Chemical compounds |
| WO2007056596A2 (en) | 2005-11-09 | 2007-05-18 | Wayne State University | Phosphoramidate derivatives of fau |
| EP2190429B1 (en) | 2007-09-10 | 2016-04-20 | Boston Biomedical, Inc. | A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors |
| JP2011522515A (ja) | 2008-04-10 | 2011-08-04 | マサチューセッツ インスティテュート オブ テクノロジー | 癌幹細胞を標的とする薬剤を同定する方法およびその使用 |
| WO2012040126A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| ES2569185T3 (es) * | 2011-03-01 | 2016-05-09 | Nucana Biomed Limited | Derivados de fosforamidato de 5-fluoro-2'-desoxiuridina para uso en el tratamiento del cáncer |
| JP2017516779A (ja) | 2014-05-28 | 2017-06-22 | アイデニクス・ファーマシューティカルズ・エルエルシー | 癌治療のためのヌクレオシド誘導体 |
| CA2945938C (en) * | 2014-06-25 | 2023-04-18 | Nucana Biomed Limited | Gemcitabine prodrugs |
| RS56752B1 (sr) * | 2014-06-25 | 2018-04-30 | NuCana plc | Formulacija koja sadrži gemcitabin-prolek |
| PL3224268T3 (pl) | 2014-11-28 | 2019-11-29 | NuCana plc | Nowe pochodne 3'-deoksyadenozyny amidofosforanów estrów aminokwasów 2' i/lub 5' jako związki przeciwnowotworowe |
| DK3197456T3 (en) * | 2015-05-14 | 2018-06-06 | NuCana plc | CANCER TREATMENTS |
| GB201522764D0 (en) | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Formulations of phosphate derivatives |
| GB201609600D0 (en) | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| GB201713916D0 (en) | 2017-08-30 | 2017-10-11 | Nucana Biomed Ltd | Treatment regimens |
| GB201715011D0 (en) | 2017-09-18 | 2017-11-01 | Nucana Biomed Ltd | Floxuridine synthesis |
-
2016
- 2016-06-01 GB GBGB1609600.0A patent/GB201609600D0/en not_active Ceased
-
2017
- 2017-05-31 JP JP2018563084A patent/JP7367910B2/ja active Active
- 2017-05-31 CA CA3025442A patent/CA3025442C/en active Active
- 2017-05-31 WO PCT/GB2017/051560 patent/WO2017207993A1/en not_active Ceased
- 2017-05-31 SG SG11201810196RA patent/SG11201810196RA/en unknown
- 2017-05-31 BR BR112018074981-8A patent/BR112018074981A2/pt not_active Application Discontinuation
- 2017-05-31 MY MYPI2018002142A patent/MY199129A/en unknown
- 2017-05-31 MX MX2018014840A patent/MX2018014840A/es unknown
- 2017-05-31 AU AU2017273124A patent/AU2017273124B2/en active Active
- 2017-05-31 CN CN201780048221.8A patent/CN109562119A/zh active Pending
- 2017-05-31 IL IL263123A patent/IL263123B/en unknown
- 2017-05-31 EP EP17728604.4A patent/EP3463384A1/en active Pending
- 2017-05-31 KR KR1020227034733A patent/KR20220142538A/ko not_active Ceased
- 2017-05-31 MA MA045129A patent/MA45129A/fr unknown
- 2017-05-31 KR KR1020187037533A patent/KR20190011770A/ko not_active Ceased
- 2017-05-31 US US16/305,162 patent/US11400107B2/en active Active
- 2017-05-31 EA EA201892803A patent/EA038030B1/ru unknown
-
2018
- 2018-11-20 ZA ZA2018/07811A patent/ZA201807811B/en unknown
- 2018-11-26 PH PH12018502491A patent/PH12018502491A1/en unknown
- 2018-11-30 CL CL2018003443A patent/CL2018003443A1/es unknown
-
2021
- 2021-10-12 CL CL2021002669A patent/CL2021002669A1/es unknown
-
2022
- 2022-02-15 JP JP2022020897A patent/JP2022051965A/ja active Pending
- 2022-08-01 US US17/878,747 patent/US20230218655A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018074981A2 (pt) | 2019-03-12 |
| CA3025442C (en) | 2024-02-20 |
| AU2017273124B2 (en) | 2022-09-29 |
| US11400107B2 (en) | 2022-08-02 |
| IL263123A (en) | 2018-12-31 |
| JP7367910B2 (ja) | 2023-10-24 |
| KR20220142538A (ko) | 2022-10-21 |
| EA038030B1 (ru) | 2021-06-25 |
| KR20190011770A (ko) | 2019-02-07 |
| GB201609600D0 (en) | 2016-07-13 |
| US20190374564A1 (en) | 2019-12-12 |
| EA201892803A1 (ru) | 2019-06-28 |
| IL263123B (en) | 2022-09-01 |
| MY199129A (en) | 2023-10-17 |
| MX2018014840A (es) | 2019-03-14 |
| US20230218655A1 (en) | 2023-07-13 |
| SG11201810196RA (en) | 2018-12-28 |
| CN109562119A (zh) | 2019-04-02 |
| CA3025442A1 (en) | 2017-12-07 |
| AU2017273124A1 (en) | 2018-12-13 |
| ZA201807811B (en) | 2024-05-30 |
| WO2017207993A1 (en) | 2017-12-07 |
| CL2018003443A1 (es) | 2019-08-09 |
| JP2022051965A (ja) | 2022-04-01 |
| EP3463384A1 (en) | 2019-04-10 |
| CL2021002669A1 (es) | 2022-05-27 |
| PH12018502491A1 (en) | 2019-09-09 |
| JP2019521971A (ja) | 2019-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL296080B1 (en) | Method for treating cancer | |
| IL269026A (en) | Methods of treating tumor | |
| IL261468A (en) | Uterine cancer treatments | |
| MA45129A (fr) | Traitements du cancer | |
| IL255261A0 (en) | Methods for treating cancer | |
| IL247001A0 (en) | Treatments for resistant acne | |
| IL263802A (en) | Cancer treatment combinations | |
| EP3413874A4 (en) | TREATMENTS FOR BLOOD CANCER | |
| EP3298448A4 (en) | OPTOGENETIC MICROSCOPE | |
| IL264443A (en) | Methods of treating prostate cancer | |
| IL265697B1 (en) | Treatment of prostate cancer | |
| PL3458052T3 (pl) | Leczenie skojarzone nowotworu | |
| MA47408A (fr) | Traitement du cancer | |
| IL268463A (en) | Cancer treatment | |
| EP3606531A4 (en) | METHOD OF TREATMENT OF CANCER | |
| EP3546020A4 (en) | CANCER TREATMENT APPARATUS | |
| EP3413927A4 (en) | CANCER THERAPY | |
| EP3593139C0 (en) | CANCER BIOMARKERS | |
| EP3576791A4 (en) | CALRETICULIN-MEDIATION CANCER TREATMENT | |
| HUE040167T2 (hu) | Rákkezelés | |
| FI20165867A7 (fi) | Valoherkiste | |
| EP3733175A4 (en) | THERAPEUTICS AGAINST CANCER | |
| LT3265565T (lt) | Vėžio, turinčio hemizigotinį praradimą, gydymo būdai | |
| MA45420A (fr) | Traitements combinés avec seribantumab | |
| EP3550976A4 (en) | METHOD FOR SYNERGISTIC TREATMENT OF CANCER |